← FDA DRUG APPROVALS

FDA ANDA · ANDA206070

PITAVASTATIN CALCIUM

pitavastatin

Sponsor: MYLAN

APPLICATION
ANDA206070
TYPE
ANDA
ORIGINAL APPROVAL
2019-04-04
LATEST ACTION
2024-09-27
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

PITAVASTATIN CALCIUMPrescription
PITAVASTATIN CALCIUM EQ 4MG BASE · TABLET · ORAL
PITAVASTATIN CALCIUMPrescription
PITAVASTATIN CALCIUM EQ 1MG BASE · TABLET · ORAL
PITAVASTATIN CALCIUMPrescription
PITAVASTATIN CALCIUM EQ 2MG BASE · TABLET · ORAL

Approval history

2024-09-27Labeling · Supplement 5 · standardAP
2024-05-29Labeling · Supplement 1 · standardAP
2019-04-04UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →